Filter News

ALSP, Inc. Obtains Patent

Published: Apr 19, 2016

SAN DIEGO, April 19, 2016 /PRNewswire/ -- ALSP, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for claims directed to a group of ALP-496-related compounds, which ALSP had earlier licensed from Columbia University.

Michael Pierschbacher, PhD, CEO, stated, "This issuance significantly increases the depth of our patent-approved pipeline of potential drug candidates."

About ALSP, Inc.
ALSP, Inc. is a privately held company in San Diego, California, developing small molecule drugs for treating neurodegenerative diseases, initially focused on TBI and Alzheimer's Disease (AD).
Further  information: www.alspinc.com

Forward-Looking Statements:
This release contains "forward-looking statements" as defined under U.S. federal securities laws.

For More Information Contact:

Michael D Pierschbacher, CEO
MPierschbacher@alspinc.com
619-922-3600

Leslie V Barrett, Investor Relations
lesliebarrett@gmail.com
415-531-4618

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/american-life-science-pharmaceuticals-inc-alsp-inc-obtains-patent-300253437.html

SOURCE American Life Science Pharmaceuticals, Inc.

Back to news